XNAS
INDV
Market cap4.51bUSD
Oct 08, Last price
35.45USD
1D
-1.88%
1Q
-12.47%
Jan 2017
898.59%
IPO
1,564.32%
Name
Indivior PLC
Chart & performance
P/E
21.06
P/S
3.57
EPS
1.68
Div yield, %
—
Shrs. gr., 5y
-2.67%
Rev. gr., 5y
13.88%
Revenues
1.24b
+4.29%
Net income
210m
+10,400.00%
CFO
-27m
L
Dividend
Oct 30, 20268.13 USD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
As a holding company, Indivior Pharmaceuticals Inc primarily focuses on the development, manufacturing, and distribution of buprenorphine-containing prescription drugs aimed at addressing opioid dependence. Key offerings in its product lineup include Suboxone Film, Suboxone Tablet, and Subutex Tablet. The company's operational footprint spans several geographical areas, namely the United States, the United Kingdom, and the 'Rest of World' segment. Indivior Pharmaceuticals Inc commenced operations on September 26, 2014, and its corporate base is situated in North Chesterfield, VA.
Related entities
Subsidiaries
RBP GLOBAL HOLDINGS LIMITED
Key people
Shaun Thaxter
Chief Executive Officer, Executive Director
Mark Crossley
Chief Financial and Operation Officer, Executive Director · since 2019
Jon Fogle
Chief Human Resource Officer
Christian Heidbreder
Chief Scientific Officer
Cary J. Claiborne
Executive Director · since 2017
Javier Rodriguez
Chief Legal Officer
Richard Simkin
Chief Commercial and Strategy Officer
Frank Stier
Chief Manufacturing and Supply Officer
Kathryn Hudson
Company Secretary
Howard Pien
Executive Chairman of the Board
Senior Non-Executive Independent Director · since 2016
Peter Bains
Non-Executive Independent Director · since 2019
A. Thomas McLellan
Non-Executive Independent Director · since 2014
Lorna Parker
Non-Executive Independent Director
Headquarters & legal address
234 BATH ROAD
SLOUGH, SLG SL1 4EE
GB
SLOUGH, SLG SL1 4EE
GB
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||